Phagenesis Limited
Phagenesis Ltd is a pioneering MedTech company dedicated to developing innovative therapies for neurogenic dysphagia, primarily using pharyngeal electrical stimulation (PES). Their flagship product, Phagenyx®, is a neurostimulation system designed to restore swallowing control in patients with severe dysphagia caused by brain injury, stroke, or other neurological conditions. The company emphasizes scientific and clinical excellence, with a history of groundbreaking research and clinical trials demonstrating the safety and efficacy of their treatments. They operate globally, with operations in the UK, Germany, Austria, and the US, and have received regulatory approvals including FDA breakthrough designation and CE marking. Their mission is to improve patient outcomes, reduce healthcare costs, and support faster recovery for patients suffering from swallowing disorders.
Industries
Nr. of Employees
small (1-50)
Phagenesis Limited
Unit 18 Enterprise House, Manchester Science Park, Manchester M15 6SE, United Kingdom
Patents
Products
Neurostimulation system for treatment of neurogenic dysphagia
A system composed of an intraluminal catheter with electrodes and a connected stimulatory base unit that delivers patient‑optimised pharyngeal electrical stimulation to restore swallowing function; indicated for adult neurogenic dysphagia in jurisdictions where authorised.
Neurostimulation system for treatment of neurogenic dysphagia
A system composed of an intraluminal catheter with electrodes and a connected stimulatory base unit that delivers patient‑optimised pharyngeal electrical stimulation to restore swallowing function; indicated for adult neurogenic dysphagia in jurisdictions where authorised.
Services
Clinical implementation support including setup instruction, clinician training materials and on‑site adoption assistance for intraluminal neurostimulation therapy for dysphagia.
Partnerships with academic centres and hospitals to run investigator‑led and company‑supported randomized trials, pilot studies and registries evaluating intraluminal neurostimulation for dysphagia.
Commercialisation activities for regulated markets including launch planning, market rollout and partnership with health systems supported by investor funding.
Clinical implementation support including setup instruction, clinician training materials and on‑site adoption assistance for intraluminal neurostimulation therapy for dysphagia.
Partnerships with academic centres and hospitals to run investigator‑led and company‑supported randomized trials, pilot studies and registries evaluating intraluminal neurostimulation for dysphagia.
Commercialisation activities for regulated markets including launch planning, market rollout and partnership with health systems supported by investor funding.
Expertise Areas
- Neurostimulation therapy for neurogenic dysphagia
- Clinical trial management and multicenter registry execution
- Neurorehabilitation and neuromodulation
- Regulatory strategy for medical devices (FDA De Novo, Breakthrough, CE marking)
Key Technologies
- Pharyngeal electrical stimulation (PES)
- Intraluminal catheter with integrated electrodes
- Patient‑specific stimulation parameter optimisation
- Device stimulator unit with on‑device sensory assessment
News & Updates
Chad Hoskins, an experienced MedTech executive, was appointed as CEO to accelerate growth and expand the use of Phagenyx® in the US and Europe.
A large study published in EClinicalMedicine shows significant benefits of Phagenyx® in treating patients with unsafe swallowing due to multiple causes.
The DGN recommends pharyngeal electrical stimulation (PES) for treating dysphagia in tracheotomized stroke patients.
Clinical studies show that PES treatment can support faster recovery and reduce hospital stay in ICU patients with dysphagia.
Case report of a COVID-19 patient treated with PES using Phagenyx® System, demonstrating rapid improvement in swallowing function.
First in a multicenter RCT to show shorter length of stay with Phagenyx® responders
Demonstrated in clinical trials that patients responding to Phagenyx® treatment had significantly shorter hospital stays.
Chad Hoskins, an experienced MedTech executive, was appointed as CEO to accelerate growth and expand the use of Phagenyx® in the US and Europe.
A large study published in EClinicalMedicine shows significant benefits of Phagenyx® in treating patients with unsafe swallowing due to multiple causes.
The DGN recommends pharyngeal electrical stimulation (PES) for treating dysphagia in tracheotomized stroke patients.
Clinical studies show that PES treatment can support faster recovery and reduce hospital stay in ICU patients with dysphagia.
Case report of a COVID-19 patient treated with PES using Phagenyx® System, demonstrating rapid improvement in swallowing function.
First in a multicenter RCT to show shorter length of stay with Phagenyx® responders
Demonstrated in clinical trials that patients responding to Phagenyx® treatment had significantly shorter hospital stays.